Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs - 2Newly discovered link between traumatic brain injury in children and epigenetic changes could help personalize treatment for recovering kids
- 3Top Fascinating Organic products: Which One Might You Want to Attempt?
- 4Voting begins in Uganda’s presidential election during internet shutdown and polling station delays
- 5The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- German foreign minister heads to China to talk rare-earth exports
- Vote In favor of Your Favored Sort Of Bevarage
- Vote in favor of Your #1 4\u00d74 SUVs
- Artemis II crew take new photo of far side of the moon
- Figure out How to Use Your Nursing Abilities for Better Compensation
- Here's what can happen if you drive under the influence of pot
- Audits of 6 American Busssiness Class Flights
- Scientists find evidence that an asteroid contains tryptophan
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
